Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Boston Scientific (BSX)

Boston Scientific approves 2026 bonus plan and two performance share programs

Neutral Impact 2 of 5 shareholder Written later

Boston Scientific's Board approved its 2026 Annual Bonus Plan and two 2026 performance share programs on November 18, 2025, covering the performance period from January 1, 2026 through December 31, 2028. The filing describes compensation terms for employees and executives, including payout ranges tied to sales, earnings and total shareholder return, but it does not report any financial results or new financial figures.

Key points

  • Board approved the 2026 Annual Bonus Plan on November 18, 2025, for the performance year January 1 to December 31, 2026.
  • Bonus pool payouts are set by the Compensation Committee at 0% to 150% of target, based on global sales, adjusted EPS, operating income and sustainability goals.
  • Two performance share programs cover January 1, 2026 to December 31, 2028, with awards of 0% to 200% of target based on relative total shareholder return and organic net sales growth.

The filing

CompanyBoston Scientific (BSX)
Form8-K, current report
Filed with the SECNov 19, 2025, 4:20 PM ET
Accession number0000885725-25-000052

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 19, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.